Compare GSK plc (GSK) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.85 (market cap $21.89B). The key difference: GSK plc is far larger — about 4.2× Consumer Discretionary Select Sector SPDR Fund's market cap, and GSK plc pays a 3.9% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| GSK | XLY | |
|---|---|---|
Market Cap | $91.88B | $21.89B |
Volume | 7,730,529 | 5,690,342 |
Sector | Health | — |
52-Week High | $61.18 | $124.52 |
52-Week Low | $43.24 | $105.64 |
Typical Hold Time | 93 Days | 114 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
XLY trades at $111.70, up 0.31% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF has underperformed the consumer staples sector in 2026, declining over 7% while XLP gained 6.6%. Analyst consensus remains unanimously bullish with 100% buy ratings, though technical indicators show RSI_6 at 82.40 suggesting potential overbought conditions near-term.
XLY faces headwinds from consumer spending shifts toward value and persistent inflation pressures, but potential catalysts include holiday retail growth projections and the 'funflation' trend. The ETF's heavy concentration in top holdings creates both opportunity and risk, with support at $110-$111 and resistance at $112-$113 defining near-term price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
